• Miscellaneous neurodegenerative disorders

Ingrezza Generic Name & Formulations

General Description

Valbenazine 40mg, 80mg; caps.

Pharmacological Class

Vesicular monoamine transporter 2 (VMAT2) inhibitor.

How Supplied

Caps 40mg—30, 90; 80mg—30; Initiation pack (4-week)—28 (7x40mg + 21x80mg)

Generic Availability


Ingrezza Indications


Tardive dyskinesia.

Ingrezza Dosage and Administration


Take with or without food. Initially 40mg once daily; increase to 80mg once daily after 1 week. For some patients, continuation of 40mg once daily may be considered. Moderate or severe hepatic impairment: 40mg once daily. Concomitant with strong CYP3A4 inducers: not recommended. Concomitant with strong CYP3A4 or CYP2D6 inhibitors, or CYP2D6 poor metabolizers: 40mg once daily.


Not established.

Ingrezza Contraindications

Not Applicable

Ingrezza Boxed Warnings

Not Applicable

Ingrezza Warnings/Precautions


Somnolence. Avoid in congenital long QT syndrome or arrhythmias associated with a prolonged QT interval. Known CYP2D6 poor metabolizers. Parkinsonism: reduce dose or discontinue if significant signs/symptoms develop. Moderate or severe hepatic impairment: reduce dose (see Adults). Pregnancy. Nursing mothers: not recommended (during and for 5 days after final dose).

Ingrezza Pharmacokinetics

See Literature

Ingrezza Interactions


See Adults. Avoid concomitant with MAOIs (eg, isocarboxazid, phenelzine, selegiline). Potentiated by strong CYP3A4 inhibitors (eg, itraconazole, ketoconazole, clarithromycin). May be potentiated by strong CYP2D6 inhibitors (eg, paroxetine, fluoxetine, quinidine). Antagonized by strong CYP3A4 inducers (eg, rifampin, carbamazepine, phenytoin, St. John's wort). Monitor digoxin levels; dose adjustment may be needed.

Ingrezza Adverse Reactions

Adverse Reactions

Somnolence, anticholinergic effects, balance disorders/fall, headache, akathisia, vomiting, nausea, arthralgia.

Ingrezza Clinical Trials

See Literature

Ingrezza Note

Not Applicable

Ingrezza Patient Counseling

See Literature